Halobetasol Propionate and Tazarotene Combination Lotion 0.01%/0.045% for Psoriasis

被引：0
|
作者：
Nicholas D. Brownstone
Tina Bhutani
John Koo
机构：
[1] University of California,Department of Dermatology, Psoriasis and Skin Treatment Center
[2] San Francisco,undefined
来源：
Current Dermatology Reports | 2021年 / 10卷
关键词：
Psoriasis; Topical therapy; Combination lotion; Halobetasol; Tazarotene;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：21 / 25
页数：4
相关论文
共 50 条
  • [1] Halobetasol Propionate and Tazarotene Combination Lotion 0.01%/0.045% for Psoriasis
    Brownstone, Nicholas D.
    Bhutani, Tina
    Koo, John
    [J]. CURRENT DERMATOLOGY REPORTS, 2021, 10 (01) : 21 - 25
  • [2] Impact of Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045% in the Management of Plaque Psoriasis in Adults
    Reddy, Vidhatha
    Myers, Bridget
    Yang, Eric J.
    Bhutani, Tina
    [J]. CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 2020, 13 : 391 - 398
  • [3] A novel halobetasol propionate 0.01%/tazarotene 0.045% fixed combination treatment for psoriasis
    Radonjic, Aleksandar
    Evans, Emily L.
    [J]. DERMATOLOGIC THERAPY, 2019, 32 (04)
  • [4] Successful Management of a Black Male With Psoriasis and Dyspigmentation Treated With Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion
    Desai, Seemal R.
    Alexis, Andrew F.
    Jacobson, Abby
    [J]. JOURNAL OF DRUGS IN DERMATOLOGY, 2020, 19 (10) : 1000 - 1004
  • [5] Assessing the Synergistic Effect of a Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion in Moderate-to-Severe Plaque Psoriasis
    Kircik, Leon H.
    Papp, Kim A.
    Gold, Linda Stein
    Harris, Susan
    Lin, Tina
    Pillai, Radhakrishnan
    [J]. JOURNAL OF DRUGS IN DERMATOLOGY, 2019, 18 (03) : 279 - 284
  • [6] Long-Term Multiple Center Experience in Treating Plaque Psoriasis With Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion
    Abduelmula, Abrahim
    Gooderham, Melinda J.
    [J]. JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2023, 27 (03) : 293 - 294
  • [7] Posttreatment maintenance of therapeutic effect with fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion for moderate-to-severe plaque psoriasis
    Lebwohl, Mark G.
    Gold, Linda Stein
    Del Rosso, James Q.
    Green, Lawrence
    Jacobson, Abby
    [J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (04) : 2068 - 2074
  • [8] Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion for Moderate-to-Severe Psoriasis: Pooled Phase 3 Analysis of Lower Extremities
    Tyring, Stephen
    Kircik, Leon H.
    Yamauchi, Paul
    Jacobson, Abby
    Lin, Tina
    [J]. JOURNAL OF DRUGS IN DERMATOLOGY, 2020, 19 (04) : 389 - 396
  • [9] An Open-Label Pilot Study to Investigate Safety and Efficacy of Fixed Combination Tazarotene 0.045% and Halobetasol Propionate 0.01% Lotion for the Treatment of Scalp Psoriasis
    Ozyurekoglu, Elif
    Kircik, Leon H.
    [J]. JOURNAL OF DRUGS IN DERMATOLOGY, 2021, 20 (11) : 1191 - 1194
  • [10] Efficacy, Safety, and Tolerability of Halobetasol Propionate 0.01%-Tazarotene 0.045% Lotion for Moderate to Severe Plaque Psoriasis in the Hispanic Population: Post Hoc Analysis
    Alexis, Andrew F.
    Yamauchi, Paul S.
    Desai, Seemal R.
    Khaselev, Nelly
    Lin, Tina
    [J]. CUTIS, 2020, 105 (03): : 150 - +
12345